Chunhui Zhang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

End Stage Renal Disease

Prognostic Factors

Anti Inflammatory

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Christina Papini, Irfan Ullah, Amalendu P Ranjan, Shuo Zhang, Qihao Wu, Krasimir A Spasov, Chunhui Zhang, Walther Mothes, Jason M Crawford, Brett D Lindenbach, Pradeep D Uchil, Priti Kumar, William L Jorgensen, Karen S Anderson
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proceedings of the National Academy of Sciences of the United States of America 121 (17) (2024)
Christina Papini, Irfan Ullah, Amalendu P Ranjan, Shuo Zhang, Qihao Wu, Krasimir A Spasov, Chunhui Zhang, Walther Mothes, Jason M Crawford, Brett D Lindenbach, Pradeep D Uchil, Priti Kumar, William L Jorgensen, Karen S Anderson
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proceedings of the National Academy of Sciences of the United States of America 121 (17) (2024)
Christina Papini, Irfan Ullah, Amalendu P Ranjan, Shuo Zhang, Qihao Wu, Krasimir A Spasov, Chunhui Zhang, Walther Mothes, Jason M Crawford, Brett D Lindenbach, Pradeep D Uchil, Priti Kumar, William L Jorgensen, Karen S Anderson
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proceedings of the National Academy of Sciences of the United States of America 121 (17) (2024)
Christina Papini, Irfan Ullah, Amalendu P Ranjan, Shuo Zhang, Qihao Wu, Krasimir A Spasov, Chunhui Zhang, Walther Mothes, Jason M Crawford, Brett D Lindenbach, Pradeep D Uchil, Priti Kumar, William L Jorgensen, Karen S Anderson
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proceedings of the National Academy of Sciences of the United States of America 121 (17) (2024)